Ensysce Biosciences, Inc.
For the period ended Jun 30, 2026. Filed Aug 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 13, 2026
ENSC$0.33-8.9%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Financial Statements (Unaudited)Consolidated Balance Sheets
Consolidated Balance Sheets
| June 30, 2026 (Unaudited) · December 31, 2025 | ||||
|---|---|---|---|---|
| Assets | ||||
| Current assets: | ||||
| Cash and cash equivalents | $676,704 | $4,310,354 | ||
| Unbilled receivable | 416,811 | 420,345 | ||
| Prepaid expenses and other current assets | 1,752,695 | 2,514,319 | ||
| Total current assets | 2,846,210 | 7,245,018 | ||
| Property and equipment, net | 111,063 | 124,129 | ||
| Other assets | - | 83,332 | ||
| Total assets | $2,957,273 | $7,452,479 | ||
| Liabilities and stockholders’ equity (deficit) | ||||
| Current liabilities: | ||||
| Accounts payable | $1,977,629 | $3,267,610 | ||
| Accrued expenses and other liabilities | 1,893,635 | 993,411 | ||
| Notes payable and accrued interest | 196,842 | 306,708 | ||
| Total current liabilities | 4,068,106 | 4,567,729 | ||
| Total liabilities | $4,068,106 | $4,567,729 | ||
| Commitments and contingencies (Note 6) | - | - | ||
| Stockholders’ equity (deficit) | ||||
| Preferred stock, $0.0001 par value, 1,500,000 shares authorized at June 30, 2026 and December 31, 2025; 6,000 shares issued at June 30, 2026 and 4,000 shares issued at December 31, 2025; 1,233 and 3,305 shares outstanding at June 30, 2026 and December 31, 2025, respectively; $1,479,600 and $3,635,500 liquidation preference at June 30, 2026 and December 31, 2025, respectively | $ | - | $ | - |
| Common stock, $0.0001 par value, 250,000,000 shares authorized at June 30, 2026 and December 31, 2025; 16,227,524 and 4,574,983 shares issued at June 30, 2026 and December 31, 2025, respectively; 16,227,518 and 4,574,977 shares outstanding at June 30, 2026 and December 31, 2025, respectively | 1,624 | 459 | ||
| Additional paid-in capital | 145,063,802 | 142,933,260 | ||
| Accumulated deficit | (145,847,123) | (139,719,999) | ||
| Total Ensysce Biosciences, Inc. stockholders’ equity (deficit) | (781,697) | 3,213,720 | ||
| Noncontrolling interests in stockholders’ equity (deficit) | (329,136) | (328,970) | ||
| Total stockholders’ equity (deficit) | (1,110,833) | 2,884,750 | ||
| Total liabilities and stockholders’ equity (deficit) | $2,957,273 | $7,452,479 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.